Levetiracetam Stragen (Levetiracetam)

Levetiracetam exerts its antiepileptic effect by binding to the synaptic vesicle protein SV2A. This binding modulates neurotransmitter release, stabilizing neuronal firing and reducing the likelihood of seizure propagation throughout the brain.

The appropriate dose of levetiracetam is determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for levetiracetam in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Levetiracetam offers a distinct mechanism of action via SV2A modulation, which differs from sodium‑channel blockers like carbamazepine. It generally has fewer drug‑enzyme interactions, a favorable pharmacokinetic profile, and can be administered intravenously, making it useful for rapid seizure control or when oral routes are unsuitable.

Levetiracetam Stragen should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain sterility and potency.

Levetiracetam Stragen is given by intravenous infusion. The infusion rate and duration are set by the treating physician, typically administered over 15 minutes to 30 minutes, depending on clinical need and patient tolerance.

Serious risks include severe allergic reactions such as anaphylaxis, significant mood or behavioral changes (including depression or suicidal thoughts), and hematologic abnormalities like low blood cell counts. Immediate medical attention is required if any of these events occur.

Levetiracetam Stragen should be avoided in patients with known hypersensitivity to levetiracetam or any component of the formulation. Caution is also advised for individuals with severe renal impairment unless dose adjustments are made, and it is not recommended for use in patients where the risk–benefit ratio is unfavorable.